Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.295
+0.007 (2.25%)
At close: Mar 9, 2026, 4:00 PM EDT
0.294
-0.001 (-0.41%)
After-hours: Mar 9, 2026, 7:57 PM EDT
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.40M in the quarter ending September 30, 2025, a decrease of -4.05%. This brings the company's revenue in the last twelve months to $5.26M, down -8.16% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.26M
Revenue Growth
-8.16%
P/S Ratio
9.93
Revenue / Employee
$250,381
Employees
21
Market Cap
52.22M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPSTV News
- 12 days ago - Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript - Seeking Alpha
- 6 weeks ago - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - GlobeNewsWire
- 7 weeks ago - Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges - Benzinga
- 7 weeks ago - Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - GlobeNewsWire
- 2 months ago - Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases - GlobeNewsWire
- 3 months ago - Plus Therapeutics Expands CNSide Assay Platform to State of California - GlobeNewsWire
- 3 months ago - Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - GlobeNewsWire